Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26468850 | 0.95 | KDM4E (0.33) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468526 | 0.94 | KDM4E (0.31) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468580 | 0.93 | KDM4E (0.32) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468544 | 0.93 | KDM4E (0.31) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468540 | 0.92 | KDM4E (0.32) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468558 | 0.92 | KDM4E (0.32) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468646 | 0.90 | — | — | |
| SCHEMBL26468576 | 0.90 | KDM4E (0.30) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468733 | 0.89 | KDM4E (0.31) | KDM4EHPGDHSD17B10L3MBTL1TSHR | |
| SCHEMBL26468644 | 0.88 | KDM4E (0.31) | KDM4EHPGDHSD17B10L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137213-A1 | NOVEL PHENANTHROLINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SFC CO., LTD. (KR) | 2023-05-04 | — | — | US | disclosed |
| US-20230137213-A1 | NOVEL PHENANTHROLINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | SFC CO., LTD. (KR) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137213-A1 | NOVEL PHENANTHROLINE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | PPOX, PAH, CRY2 | KDM4E 907/4885HPGD 712/4885HSD17B10 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.